Table 2.
Subgroup analysis of overall survival and cancer-specific survival.
| Subgroup | Studies | HR (95% CI) | P-value | Heterogeneity | |
|---|---|---|---|---|---|
| I2 (%) | P-value | ||||
| OVERALL SURVIVAL | |||||
| Year of publication | |||||
| 2018–2019 | 5 | 1.74 (1.47–2.07) | <0.001 | 0.0 | 0.515 |
| 2015–2017 | 7 | 1.84 (1.59–2.12) | <0.001 | 0.0 | 0.498 |
| Continent | |||||
| Asia | 10 | 1.79 (1.58–2.04) | <0.001 | 0.0 | 0.660 |
| Europe | 2 | 1.94 (1.28–2.95) | 0.002 | 51.1 | 0.153 |
| Country | |||||
| China | 2 | 1.68 (1.26–2.24) | <0.001 | 41.8 | 0.190 |
| South Korea | 6 | 1.78 (1.54–2.06) | <0.001 | 0.0 | 0.683 |
| Japan | 2 | 2.44 (1.47–4.08) | 0.001 | 0.0 | 0.564 |
| Site of carcinoma | |||||
| Upper Tract Urothelial Cancer | 3 | 1.91 (1.57–2.33) | <0.001 | 0.0 | 0.791 |
| Renal Cell Carcinoma | 4 | 1.74 (1.47–2.07) | <0.001 | 0.0 | 0.803 |
| Prostate Cancer | 2 | 1.47 (0.82–2.64) | 0.195 | 60.5 | 0.111 |
| Bladder Cancer | 3 | 1.80 (1.43–2.27) | <0.001 | 48.2 | 0.145 |
| Sample size | |||||
| >200 | 7 | 1.73 (1.53–1.96) | <0.001 | 0.0 | 0.718 |
| <200 | 5 | 2.09 (1.64–2.66) | <0.001 | 0.0 | 0.511 |
| Cancer stage | |||||
| Non–metastatic | 9 | 1.78 (1.58–2.01) | <0.001 | 0.0 | 0.543 |
| Metastatic | 3 | 1.89 (1.42–2.53) | <0.001 | 0.0 | 0.420 |
| Cut–off value | |||||
| >1.3 | 5 | 1.84 (1.52–2.23) | <0.001 | 0.0 | 0.439 |
| ≤1.3 | 7 | 1.77 (1.55–2.03) | <0.001 | 0.0 | 0.549 |
| NOS score | |||||
| ≥7 | 9 | 1.74 (1.55–1.95) | <0.001 | 0.0 | 0.748 |
| <7 | 3 | 2.52 (1.73–3.67) | <0.001 | 0.0 | 0.835 |
| CANCER–SPECIFIC SURVIVAL | |||||
| Year of publication | |||||
| 2018–2019 | 6 | 1.90 (1.58–2.28) | <0.001 | 36.6 | 0.162 |
| 2017 | 5 | 2.45 (1.96–3.07) | <0.001 | 0.0 | 0.478 |
| Continent | |||||
| Asia | 9 | 2.14 (1.84–2.48) | <0.001 | 0.0 | 0.581 |
| Europe | 2 | 2.60 (0.61–11.15) | 0.198 | 86.2 | 0.007 |
| Country | |||||
| South Korea | 6 | 2.02 (1.71–2.40) | <0.001 | 0.0 | 0.503 |
| Japan | 2 | 2.49 (1.58–3.93) | <0.001 | 0.0 | 0.471 |
| Turkey | 2 | 2.60 (0.61–11.15) | 0.198 | 86.2 | 0.007 |
| Site of carcinoma | |||||
| Upper Tract Urothelial Cancer | 3 | 2.46 (1.93–3.13) | <0.001 | 0.0 | 0.872 |
| Renal Cell Carcinoma | 5 | 1.87 (1.51–2.31) | <0.001 | 29.1 | 0.228 |
| Bladder Cancer | 3 | 2.71 (1.39–5.31) | 0.004 | 65.0 | 0.057 |
| Sample size | |||||
| > 200 | 7 | 2.13 (1.81–2.52) | <0.001 | 20.3 | 0.274 |
| <200 | 4 | 2.39 (1.48–3.85) | <0.001 | 55.6 | 0.080 |
| Cancer stage | |||||
| Non–metastatic | 9 | 2.21 (1.89–2.60) | <0.001 | 32.6 | 0.157 |
| Metastatic | 2 | 1.74 (1.28–2.37) | <0.001 | 0.0 | 0.415 |
| Cut–off value | |||||
| >1.3 | 5 | 2.18 (1.76–2.69) | <0.001 | 25.7 | 0.250 |
| ≤1.3 | 6 | 2.05 (1.70–2.48) | <0.001 | 43.4 | 0.116 |
| NOS score | |||||
| ≥7 | 8 | 2.14 (1.83–2.50) | <0.001 | 0.0 | 0.472 |
| <7 | 3 | 2.31 (1.10–4.83) | 0.027 | 73.3 | 0.024 |
HR, hazard ratio; CI, confidence interval; NOS, Newcastle-Ottawa Scale.